DK0981549T4 - Anvendelse af et inhiberende stof til forbedring af regenereringen af neutroner - Google Patents

Anvendelse af et inhiberende stof til forbedring af regenereringen af neutroner

Info

Publication number
DK0981549T4
DK0981549T4 DK98924307T DK98924307T DK0981549T4 DK 0981549 T4 DK0981549 T4 DK 0981549T4 DK 98924307 T DK98924307 T DK 98924307T DK 98924307 T DK98924307 T DK 98924307T DK 0981549 T4 DK0981549 T4 DK 0981549T4
Authority
DK
Denmark
Prior art keywords
regeneration
neutrons
improve
inhibitory agent
neuronal
Prior art date
Application number
DK98924307T
Other languages
Danish (da)
English (en)
Other versions
DK0981549T3 (da
Inventor
H W Prof Dr Mueller
Christine Dr Stichel-Gunkel
Original Assignee
Neuraxo Biopharmaceuticals Gmb
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8226794&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0981549(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Neuraxo Biopharmaceuticals Gmb filed Critical Neuraxo Biopharmaceuticals Gmb
Publication of DK0981549T3 publication Critical patent/DK0981549T3/da
Application granted granted Critical
Publication of DK0981549T4 publication Critical patent/DK0981549T4/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK98924307T 1997-05-14 1998-05-13 Anvendelse af et inhiberende stof til forbedring af regenereringen af neutroner DK0981549T4 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP97107846A EP0878480A1 (de) 1997-05-14 1997-05-14 Verfahren zur Förderung der Nerven-Regenerierung
PCT/EP1998/002808 WO1998051708A1 (en) 1997-05-14 1998-05-13 A method for the improvement of neuronal regeneration

Publications (2)

Publication Number Publication Date
DK0981549T3 DK0981549T3 (da) 2003-02-10
DK0981549T4 true DK0981549T4 (da) 2007-10-29

Family

ID=8226794

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98924307T DK0981549T4 (da) 1997-05-14 1998-05-13 Anvendelse af et inhiberende stof til forbedring af regenereringen af neutroner

Country Status (8)

Country Link
US (3) US20020115598A1 (de)
EP (2) EP0878480A1 (de)
AT (1) ATE224915T1 (de)
AU (1) AU7654298A (de)
DE (1) DE69808281T3 (de)
DK (1) DK0981549T4 (de)
ES (1) ES2180175T5 (de)
WO (1) WO1998051708A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0878480A1 (de) * 1997-05-14 1998-11-18 H.W. Prof. Dr. Müller Verfahren zur Förderung der Nerven-Regenerierung
US6200974B1 (en) 1997-10-24 2001-03-13 Zeneca Limited Phenanthroline derivatives
CN101664409A (zh) * 2001-12-06 2010-03-10 法布罗根股份有限公司 低氧诱导因子(HIF)α的稳定化
CN100522946C (zh) * 2001-12-06 2009-08-05 法布罗根股份有限公司 低氧诱导因子(HIF)α的稳定化
US7618940B2 (en) * 2002-12-06 2009-11-17 Fibrogen, Inc. Fat regulation
US8124582B2 (en) * 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
DE10314082A1 (de) * 2003-03-28 2004-10-21 Mcs Micro Carrier Systems Gmbh Biodegradierbares injizierbares Implantat
KR20080044845A (ko) * 2005-09-02 2008-05-21 노이락소 바이오파르마슈티컬즈 게엠베하 철 킬레이트제를 포함하는 약학적 조성물
WO2007048846A1 (de) * 2005-10-27 2007-05-03 Neuraxo Biopharmaceuticals Gmbh Verwendung von eisen chelatisierenden verbindungen, zyklisches adenosinmonophosphat erhöhende verbindungen oder kombinationen davon zur behandlung von axonalen läsionen im zns
EP2000134A1 (de) * 2007-06-06 2008-12-10 Neuraxo Biopharmaceuticals GmbH Verwendung einer Substanz zur Behandlung von Verletzungen des peripheren Nervensystems
US9649381B2 (en) 2013-11-06 2017-05-16 Wayne State University Transporter protein-coupled nanodevices for targeted drug delivery

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4214000A (en) † 1978-10-30 1980-07-22 Johnson & Johnson Zinc salt of all-trans-retinoic acid for the treatment of acne
DE3002989A1 (de) 1980-01-29 1981-07-30 Hoechst Ag, 6000 Frankfurt Hydroxyphenyl-thiazol, -thiazolin und -thiazolidin-carbonsaeuren, verfahren zu ihrer herstellung und ihre verwendung zur beeinflussung des kollagenstoffwechsels
CA1251729A (en) * 1982-05-19 1989-03-28 Steffen Gay In vitro diagnostic methods using monoclonal antibodies against connective tissue proteins
DE3432094A1 (de) 1984-08-31 1986-03-06 Hoechst Ag, 6230 Frankfurt Ester der pyridin-2,4- und -2,5- dicarbonsaeure als arzneimittel zur inhibierung der prolin- und lysinhydroxylase
US5021404A (en) † 1988-04-20 1991-06-04 The Children's Medical Center Corporation Angiostatic collagen modulators
AU3943793A (en) * 1992-04-01 1993-11-08 Whittier Institute For Diabetes And Endocrinology, The Methods of inhibiting or enhancing scar formation in the CNS
JPH06103773A (ja) † 1992-09-16 1994-04-15 Hitachi Ltd 半導体記憶装置
CA2117889A1 (en) * 1993-02-11 1994-08-18 Martin E. Schwab A combination of neurotrophin and antibody directed toward myelin-associated neurite growth inhibitory protein promotes central nervous system regeneration
JPH09503790A (ja) * 1993-10-15 1997-04-15 トーマス ジェファーソン ユニバーシティ 核原発ガン遺伝子に向けられたアンチセンス化合物による細胞外マトリクス合成の阻害
WO1995013291A1 (en) * 1993-11-08 1995-05-18 New York University Neuron-glia cell adhesion molecule, ng-cam, in treatment of nerve damage
US5567609A (en) * 1994-06-30 1996-10-22 University Of Kansas Medical Center Use of isolated domains of type IV collagen to modify cell and tissue interactions
EP0878480A1 (de) * 1997-05-14 1998-11-18 H.W. Prof. Dr. Müller Verfahren zur Förderung der Nerven-Regenerierung

Also Published As

Publication number Publication date
US7208153B2 (en) 2007-04-24
DE69808281T2 (de) 2003-01-16
AU7654298A (en) 1998-12-08
DK0981549T3 (da) 2003-02-10
DE69808281D1 (de) 2002-10-31
DE69808281T3 (de) 2008-01-24
US20020115598A1 (en) 2002-08-22
US20070231330A1 (en) 2007-10-04
WO1998051708A1 (en) 1998-11-19
EP0878480A1 (de) 1998-11-18
ATE224915T1 (de) 2002-10-15
EP0981549A1 (de) 2000-03-01
EP0981549B1 (de) 2002-09-25
EP0981549B2 (de) 2007-06-27
US20050118177A1 (en) 2005-06-02
EP0981549B9 (de) 2008-02-27
ES2180175T5 (es) 2008-02-01
ES2180175T3 (es) 2003-02-01

Similar Documents

Publication Publication Date Title
ATE248153T1 (de) Neue benzoxazole
DK0971713T3 (da) Anvendelse af cholinesteraseinhibitorer til behandling af opmærksomhedsforstyrrelser
ES2145915T3 (es) Derivados estereoquimicos de la wortmannina.
DK0840732T3 (da) Substituerede benzolactamforbindelser som substans P-antagonister
ES2193252T3 (es) Quinolonas y su uso terapeutico.
IL122782A0 (en) Pharmaceutical compositions for treatment and prevention of neoplasms with salts of aminoimidazole carboxamide and 5-amino or substituted amino 1,2,3-triazoles
ATE225351T1 (de) Thienopyridin und thienopyrimidinderivate und ihre verwendung als entzündungshemmende mittel
DK0981549T4 (da) Anvendelse af et inhiberende stof til forbedring af regenereringen af neutroner
MX9205678A (es) Heteroarilaminas como nuevos inhibidores de la acetilcolinesterasa.
NO880772L (no) Fremgangsmaate til behandling av slam fra avloepsvann.
DK0938326T3 (da) Syntetiske phosphopeptider til behandling af knoglesygdomme
DK0881300T3 (da) Metode til at identificere forbindelser til inhibition af neoplastiske læsioner
FI953899A (fi) Substituoituja atsolonijohdannaisia Helicobacterin aiheuttamien sairauksien hoitamiseksi
ID21534A (id) Konstruksi asam nukleat untuk terapi gen dimana aktifitasnya dipengaruhi oleh inhibitor kinase yang tergantung pada siklin
BR9506552A (pt) Método de inibição de integrase retroviral
DK0983275T3 (da) Nye triptolidderivater, der er nyttige til behandling af autoimmune sygdomme
DE69111382D1 (de) Polymerisationsinhibitor und Inhibierungsmethode für Vinylverbindungen.
ATE419346T1 (de) Hemmung der bildung von atherosklerotischen wunden mittels afabp antisens nukleinsäuren
DE69414891D1 (de) System zum Erfassen der Rotorbewegung
DK0869785T3 (da) 4-Hydroxycoumarin-3-carboxyamider til behandling af ikke-insulinafhængig diabetes mellitus
DE59607755D1 (de) Weggeber zur erfassung des verstellweges eines stellglieds
DE3886423D1 (de) Zeitlich begrenztes oder permanentes Absperren der Bohrung eines Rohres.
ID20165A (id) Penggunaan asam 2-(3,4-dimetoksisinamoil)aminobenzoat untuk pembuatan obat untuk pengobatan atau pencegahan restenosis
DE69614620D1 (de) Methoden zum Nachweis von menslichem Parvovirus
FR2725552B1 (fr) Procede de decontamination partielle alpha d'un effluent aqueux